Navigation Links
New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease
Date:6/15/2010

a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
2. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
3. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
4. Reaction Progress Kinetic Analysis to Study Organic Reactions: Free On-Demand Online Seminar
5. Study sheds light into the nature of embryonic stem cells
6. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
7. Carolina Conceptions Announces New Egg Freezing Study to Help Women Preserve their Fertility
8. Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
9. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
11. AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... the leading online,information source for life science ... launched the 2nd Edition of the Southern ... science community of the Southeastern,United States. The ... that constitute the dynamic biopharmaceutical industry in ...
... Celgosivir 4-Week Viral Kinetics Study Data on ... Monday December 3, ... Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results ...
... NOLabs AB, the Swedish,medtech company developing innovative ... Technology, today reported that it has,achieved another ... new line of,products for wounds infected by ... a bacterium that is particularly,troublesome in hospital-acquired ...
Cached Biology Technology:BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign 2MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Lopez starred in the film "Anaconda," the world,s ... in Colombia co-organized by Carlos Jaramillo, staff scientist ... and Jonathan Bloch, curator of vertebrate paleontology at ... History, unearthed fossil remains of a new snake ...
... ANN ARBOR, Mich. University of Michigan scientists report ... shown to kill many other microbes, may be able ... nearly all cystic fibrosis deaths. Cystic fibrosis ... children and adults in the United States. Patients have ...
... Md. (Feb 4, 2009) - Training people to avoid ... the laboratory helped them to later maintain their balance ... the Journal of Neurophysiology . The study ... prevention strategies that can be generalized to a variety ...
Cached Biology News:World's largest snake discovered in fossilized rainforest 2Nanoemulsion potent against superbugs that kill cystic fibrosis patients 2Nanoemulsion potent against superbugs that kill cystic fibrosis patients 3Research model may one day 'inoculate' elderly against slip-related falls 2Research model may one day 'inoculate' elderly against slip-related falls 3
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... a nucleolar protein of bakers yeast, ... protein is essential for yeast viability ... The human homologue of Nop1p is ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... Protein G bind specifically to Fc regions ... Protein G conjugates are commonly used as ... immunoglobulin subtypes from serum, hybridoma ascites fluids, ... These reagents are also commonly used to ...
Biology Products: